_id
690dad6eccc777a4e85d0a0d
Ticker
ALMS
Name
Alumis Inc
Exchange
NASDAQ
Address
280 East Grand Avenue, South San Francisco, CA, United States, 94080
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.alumis.com
Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Last Close
23.24
Volume
288965
Current Price
23.755
Change
-0.105
Last Updated
2026-01-20T15:12:28.933Z
Image
data:image/webp;base64,UklGRmgBAABXRUJQVlA4IFwBAABwCQCdASpAAEAAPtFUpUyoJKOiLBgMyQAaCWgAy30O7tA3nwH4/ME6/+Nq6sJb0eUz+o+V3RK3UMlBaRzliJPKDGqOBHjOQengZjIk2aGrg9+Y0gAA/vfwiTswkN7dmOO/jdsz6RfpfB/2RvZ37VI+hxlWWu90GvWj/imRFW9LWKfFmpsvYUCQNdn+50K/TAdFMzQR+qKTEo+/cTA/dJEkFDS4tAHTAT8vInj6fRvA1ZSRHIo6INQM2bWy4rUWnMbcdSLOnkVqEx8NNtjmz77vdm2LgO/xvUDfecXArrLC76GNDRr4Ua/yZimEXPw/TXMTvCHrtmKiNWVg88abYD/feOyC5o86j/FInPS2c+Y++iIzPDvybDrCr1a52HxJaDlooUpGEhMmRcoSSn/0kbup2BMnxOamCZCwb73uQa5tO2BqgHCZJbz7AXJn2Xs4j3Cfxre0mt4UOE9pwAA=
Ipo Date
2024-06-28T00:00:00.000Z
Market Cap
2975124992
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9563529411764705
Sentiment Sources
17
Rating
4.6667
Target Price
37.2857
Strong Buy
4
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
2066000
Cost Of Revenue
-
Gross Profit
2066000
Operating Expenses
117358000
Operating Income
-115292000
Interest Expense
-
Pretax Income
-110752000
Net Income
-110752000
Eps
-1.0638056411571448
Dividends Per Share
-
Shares Outstanding
117505995
Income Tax Expense
-
EBITDA
-109836000
Operating Margin
-5580.445304937077
Total Other Income Expense Net
4540000
Cash
65257000
Short Term Investments
312467000
Receivables
3637000
Inventories
-
Total Current Assets
393290000
Property Plant Equipment
36569000
Total Assets
488014000
Payables
4554000
Short Term Debt
4412000
Long Term Debt
-
Total Liabilities
103241000
Equity
384773000
Bs_currency_symbol
USD
Depreciation
916000
Change In Working Capital
-10202000
Cash From Operations
-110909000
Capital Expenditures
0
Cash From Investing
24036000
Cash From Financing
0
Net Change In Cash
-86873000
Cf_currency_symbol
USD
PE
-
PB
6.42746520016997
ROE
-28.783724429728696
ROA
-22.694430897474252
FCF
-110909000
Fcf Percent
-53.68296224588577
Piotroski FScore
0
Health Score
26
Deep Value Investing Score
3.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
5.3
Garp Investing Score
2.5
Growth Investing Score
1.5
Momentum Investing Score
4.5
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
3.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
2066000
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
2066000
Quarters > 0 > income Statement > operating Expenses
117358000
Quarters > 0 > income Statement > operating Income
-115292000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-110752000
Quarters > 0 > income Statement > net Income
-110752000
Quarters > 0 > income Statement > eps
-1.0638056411571448
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
104109243
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-109836000
Quarters > 0 > income Statement > operating Margin
-5580.445304937077
Quarters > 0 > income Statement > total Other Income Expense Net
4540000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
65257000
Quarters > 0 > balance Sheet > short Term Investments
312467000
Quarters > 0 > balance Sheet > receivables
3637000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
393290000
Quarters > 0 > balance Sheet > property Plant Equipment
36569000
Quarters > 0 > balance Sheet > total Assets
488014000
Quarters > 0 > balance Sheet > payables
4554000
Quarters > 0 > balance Sheet > short Term Debt
4412000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
103241000
Quarters > 0 > balance Sheet > equity
384773000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-110752000
Quarters > 0 > cash Flow > depreciation
916000
Quarters > 0 > cash Flow > change In Working Capital
-10202000
Quarters > 0 > cash Flow > cash From Operations
-110909000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
24036000
Quarters > 0 > cash Flow > cash From Financing
0
Quarters > 0 > cash Flow > net Change In Cash
-86873000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-1.0638056411571448
Quarters > 0 > ratios > PB
6.42746520016997
Quarters > 0 > ratios > ROE
-28.783724429728696
Quarters > 0 > ratios > ROA
-22.694430897474252
Quarters > 0 > ratios > FCF
-110909000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-53.68296224588577
Quarters > 0 > health Score
26
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
2666000
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
2666000
Quarters > 1 > income Statement > operating Expenses
143205000
Quarters > 1 > income Statement > operating Income
-140539000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
50760000
Quarters > 1 > income Statement > net Income
59321000
Quarters > 1 > income Statement > eps
0.774062859186286
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
76635895
Quarters > 1 > income Statement > income Tax Expense
-8561000
Quarters > 1 > income Statement > EBITDA
-119969000
Quarters > 1 > income Statement > operating Margin
-5271.530382595649
Quarters > 1 > income Statement > total Other Income Expense Net
191299000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
151753000
Quarters > 1 > balance Sheet > short Term Investments
334568000
Quarters > 1 > balance Sheet > receivables
7857000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
517558000
Quarters > 1 > balance Sheet > property Plant Equipment
38551000
Quarters > 1 > balance Sheet > total Assets
610925000
Quarters > 1 > balance Sheet > payables
14981000
Quarters > 1 > balance Sheet > short Term Debt
4058000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
125598000
Quarters > 1 > balance Sheet > equity
485327000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
59321000
Quarters > 1 > cash Flow > depreciation
870000
Quarters > 1 > cash Flow > change In Working Capital
3540000
Quarters > 1 > cash Flow > cash From Operations
-106352000
Quarters > 1 > cash Flow > capital Expenditures
616000
Quarters > 1 > cash Flow > cash From Investing
129400000
Quarters > 1 > cash Flow > cash From Financing
749000
Quarters > 1 > cash Flow > net Change In Cash
23577000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
0.774062859186286
Quarters > 1 > ratios > PB
3.751049675218976
Quarters > 1 > ratios > ROE
12.222893018521534
Quarters > 1 > ratios > ROA
9.71002987273397
Quarters > 1 > ratios > FCF
-106968000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
-40.12303075768942
Quarters > 1 > health Score
63
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
17389000
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
17389000
Quarters > 2 > income Statement > operating Expenses
118917000
Quarters > 2 > income Statement > operating Income
-101528000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-98963000
Quarters > 2 > income Statement > net Income
-98963000
Quarters > 2 > income Statement > eps
-1.8231856794211612
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
54280264
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-100685000
Quarters > 2 > income Statement > operating Margin
-583.8633618954511
Quarters > 2 > income Statement > total Other Income Expense Net
2565000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
128543000
Quarters > 2 > balance Sheet > short Term Investments
80206000
Quarters > 2 > balance Sheet > receivables
1287000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
225530000
Quarters > 2 > balance Sheet > property Plant Equipment
34561000
Quarters > 2 > balance Sheet > total Assets
261298000
Quarters > 2 > balance Sheet > payables
7473000
Quarters > 2 > balance Sheet > short Term Debt
2545000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
92984000
Quarters > 2 > balance Sheet > equity
168314000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-98963000
Quarters > 2 > cash Flow > depreciation
843000
Quarters > 2 > cash Flow > change In Working Capital
11487000
Quarters > 2 > cash Flow > cash From Operations
-80355000
Quarters > 2 > cash Flow > capital Expenditures
37000
Quarters > 2 > cash Flow > cash From Investing
39428000
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
-40983000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-1.8231856794211612
Quarters > 2 > ratios > PB
7.660846223843531
Quarters > 2 > ratios > ROE
-58.796653873118096
Quarters > 2 > ratios > ROA
-37.8736155653698
Quarters > 2 > ratios > FCF
-80392000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-4.6231525677152225
Quarters > 2 > health Score
23
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
3036000
Quarters > 3 > income Statement > cost Of Revenue
820000
Quarters > 3 > income Statement > gross Profit
-820000
Quarters > 3 > income Statement > operating Expenses
97802000
Quarters > 3 > income Statement > operating Income
-98622000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-94759000
Quarters > 3 > income Statement > net Income
-94759000
Quarters > 3 > income Statement > eps
-1.7628852298815623
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
53752223
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-93939000
Quarters > 3 > income Statement > operating Margin
-3248.4189723320155
Quarters > 3 > income Statement > total Other Income Expense Net
3863000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
169526000
Quarters > 3 > balance Sheet > short Term Investments
118737000
Quarters > 3 > balance Sheet > receivables
1812000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
306188000
Quarters > 3 > balance Sheet > property Plant Equipment
33691000
Quarters > 3 > balance Sheet > total Assets
340992000
Quarters > 3 > balance Sheet > payables
9624000
Quarters > 3 > balance Sheet > short Term Debt
1557000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
80889000
Quarters > 3 > balance Sheet > equity
260103000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-94759000
Quarters > 3 > cash Flow > depreciation
820000
Quarters > 3 > cash Flow > change In Working Capital
14486000
Quarters > 3 > cash Flow > cash From Operations
-74764000
Quarters > 3 > cash Flow > capital Expenditures
366000
Quarters > 3 > cash Flow > cash From Investing
30950000
Quarters > 3 > cash Flow > cash From Financing
5000
Quarters > 3 > cash Flow > net Change In Cash
-43891000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-1.7628852298815623
Quarters > 3 > ratios > PB
4.909147750564199
Quarters > 3 > ratios > ROE
-36.43133681656882
Quarters > 3 > ratios > ROA
-27.789214996246248
Quarters > 3 > ratios > FCF
-75130000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-24.746376811594203
Quarters > 3 > health Score
30
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
3152000
Annuals > 0 > income Statement > gross Profit
-3152000
Annuals > 0 > income Statement > operating Expenses
297602000
Annuals > 0 > income Statement > operating Income
-300754000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-294233000
Annuals > 0 > income Statement > net Income
-294233000
Annuals > 0 > income Statement > eps
-10.381567678006805
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
28341866
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-297602000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
6521000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
169526000
Annuals > 0 > balance Sheet > short Term Investments
118737000
Annuals > 0 > balance Sheet > receivables
1812000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
306188000
Annuals > 0 > balance Sheet > property Plant Equipment
33691000
Annuals > 0 > balance Sheet > total Assets
340992000
Annuals > 0 > balance Sheet > payables
9624000
Annuals > 0 > balance Sheet > short Term Debt
1557000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
80889000
Annuals > 0 > balance Sheet > equity
260103000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-294233000
Annuals > 0 > cash Flow > depreciation
3152000
Annuals > 0 > cash Flow > change In Working Capital
14760000
Annuals > 0 > cash Flow > cash From Operations
-255078000
Annuals > 0 > cash Flow > capital Expenditures
1732000
Annuals > 0 > cash Flow > cash From Investing
-113790000
Annuals > 0 > cash Flow > cash From Financing
492367000
Annuals > 0 > cash Flow > net Change In Cash
123499000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-10.381567678006805
Annuals > 0 > ratios > PB
2.588440067319485
Annuals > 0 > ratios > ROE
-113.12172485515353
Annuals > 0 > ratios > ROA
-86.28736158033034
Annuals > 0 > ratios > FCF
-256810000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
1284000
Annuals > 1 > income Statement > gross Profit
-1284000
Annuals > 1 > income Statement > operating Expenses
158174000
Annuals > 1 > income Statement > operating Income
-158174000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-154993000
Annuals > 1 > income Statement > net Income
-154993000
Annuals > 1 > income Statement > eps
-2.98956138819821
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
51844729
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-156890000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
3181000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
45996000
Annuals > 1 > balance Sheet > short Term Investments
2956000
Annuals > 1 > balance Sheet > receivables
722000
Annuals > 1 > balance Sheet > inventories
-95000
Annuals > 1 > balance Sheet > total Current Assets
53357000
Annuals > 1 > balance Sheet > property Plant Equipment
35224000
Annuals > 1 > balance Sheet > total Assets
89612000
Annuals > 1 > balance Sheet > payables
1118000
Annuals > 1 > balance Sheet > short Term Debt
1720000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
428872000
Annuals > 1 > balance Sheet > equity
-339260000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-154993000
Annuals > 1 > cash Flow > depreciation
1284000
Annuals > 1 > cash Flow > change In Working Capital
12058000
Annuals > 1 > cash Flow > cash From Operations
-129975000
Annuals > 1 > cash Flow > capital Expenditures
4499000
Annuals > 1 > cash Flow > cash From Investing
60472000
Annuals > 1 > cash Flow > cash From Financing
89682000
Annuals > 1 > cash Flow > net Change In Cash
20179000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-2.98956138819821
Annuals > 1 > ratios > PB
-3.6301701862730646
Annuals > 1 > ratios > ROE
45.68560985674704
Annuals > 1 > ratios > ROA
-172.96009463018345
Annuals > 1 > ratios > FCF
-134474000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
250000
Annuals > 2 > income Statement > gross Profit
-250000
Annuals > 2 > income Statement > operating Expenses
113600000
Annuals > 2 > income Statement > operating Income
-113850000
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-111930000
Annuals > 2 > income Statement > net Income
-111930000
Annuals > 2 > income Statement > eps
-14.928733403737878
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
7497622
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-113600000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
1920000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
25610000
Annuals > 2 > balance Sheet > short Term Investments
67255000
Annuals > 2 > balance Sheet > receivables
500000
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
102555000
Annuals > 2 > balance Sheet > property Plant Equipment
4475000
Annuals > 2 > balance Sheet > total Assets
108168000
Annuals > 2 > balance Sheet > payables
1720000
Annuals > 2 > balance Sheet > short Term Debt
1310000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
303410000
Annuals > 2 > balance Sheet > equity
-195242000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-111930000
Annuals > 2 > cash Flow > depreciation
250000
Annuals > 2 > cash Flow > change In Working Capital
-1916000
Annuals > 2 > cash Flow > cash From Operations
-107722000
Annuals > 2 > cash Flow > capital Expenditures
2406000
Annuals > 2 > cash Flow > cash From Investing
-68751000
Annuals > 2 > cash Flow > cash From Financing
101627000
Annuals > 2 > cash Flow > net Change In Cash
-74846000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-14.928733403737878
Annuals > 2 > ratios > PB
-0.9122320536052694
Annuals > 2 > ratios > ROE
57.32885342293154
Annuals > 2 > ratios > ROA
-103.4779232305303
Annuals > 2 > ratios > FCF
-110128000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
30
Valuation > metrics > PE
-1.0638056411571448
Valuation > metrics > PB
6.42746520016997
Valuation > final Score
20
Valuation > verdict
114.2% Overvalued
Profitability > metrics > ROE
-28.783724429728696
Profitability > metrics > ROA
-28.160390551501436
Profitability > metrics > Net Margin
-53.606969990319456
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.2683166438393546
Risk > metrics > Interest Coverage
-125.8646288209607
Risk > final Score
-443
Risk > verdict
High
Liquidity > metrics > Current Ratio
43.86459959848316
Liquidity > metrics > Quick Ratio
43.86459959848316
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
62.48950324781024
Prev Valuations > 1
20
Prev Valuations > 2
30.908522494358007
Prev Profitabilities > 0
84
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
57
Prev Risks > 1
-188
Prev Risks > 2
-421
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:22:20.740Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-13
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-1.06
Earnings History > 0 > eps Estimate
-1
Earnings History > 0 > eps Difference
-0.06
Earnings History > 0 > surprise Percent
-6
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-13
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
0.77
Earnings History > 1 > eps Estimate
-1.3875
Earnings History > 1 > eps Difference
2.1575
Earnings History > 1 > surprise Percent
155.4955
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-14
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-1.82
Earnings History > 2 > eps Estimate
-1.4233
Earnings History > 2 > eps Difference
-0.3967
Earnings History > 2 > surprise Percent
-27.8718
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-03-19
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-1.74
Earnings History > 3 > eps Estimate
-1.32
Earnings History > 3 > eps Difference
-0.42
Earnings History > 3 > surprise Percent
-31.8182
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-13
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-1.73
Earnings History > 4 > eps Estimate
-1.805
Earnings History > 4 > eps Difference
0.075
Earnings History > 4 > surprise Percent
4.1551
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-13
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
AfterMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-1.0387
Earnings History > 5 > eps Estimate
-1.67
Earnings History > 5 > eps Difference
0.6313
Earnings History > 5 > surprise Percent
37.8024
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-29
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
-4.5
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
-4.5
Earnings History > 6 > surprise Percent
-
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AThis Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Benzinga
Read more →Chardan Capital initiates coverage on Alumis stock with Buy rating Investing.com
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$37.2857
Analyst Picks
Strong Buy
4
Buy
2
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Alumis Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-1.06
EPS Estimate
-1
EPS Difference
-0.06
Surprise Percent
-6%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.